Creative Biolabs is a well-recognized global leader in providing bispecific antibodies (BsAbs) development services. With our extensive experience in antibody engineering and the advanced BsAb production platform, we are dedicated to provide our clients with highly customized dual-targeting IgG (DT-IgG) generation services.
In the recent years, dual targeting with BsAbs has rose up as an alternative to combination therapy or use of mixtures. The concept of dual targeting with BsAbs is based on the targeting of multiple disease-modifying molecules with one drug. From a technological perspective, this enables development less complex on account of manufacturing, preclinical and clinical testing is decreased to a single, bispecific molecule. Besides, compared to therapy with combinations drugs, therapy using a single dual-targeting drug should be less complicated for patients.
Dual targeting strategies with BsAbs enable to be divided into two categories. The first type is those directly work on target structures, such as cell surface receptors or soluble factors. Another type is that utilizes dual targeting for delivery (retargeting) of a therapeutically active moiety, for example, effector molecules and effector cells. Direct actions comprise binding and neutralization of two ligands or two receptors, activation of two receptors, neutralization of a receptor and a ligand, activation of one receptor and neutralization of another receptor or a soluble factor, but also neutralization by binding to different epitopes of one receptor or ligand. Indirect actions contain Fc region-mediated ADCC and CDC, retargeting of immune effector cells via a further binding site, targeting of an effector molecule, such as a cytokine, a toxin, or a prodrug-converting enzyme. Direct and indirect actions enable to be integrated within one molecule to further enhance efficacy.
Figure 1. This figure shows the structure of dual-targeting agents. (Schubert, I., 2012)
Applications of dual targeting strategies are similarly manifold, with the major exhibition being cancer therapy and the treatment of infectious and inﬂammatory diseases. The same mechanisms used for combination therapy of antibodies are able to be targeted with BsAbs. Therefore, a number of diseases mediators and signaling pathways enable to be addressed and simultaneously restrained by the DT-IgG. This contains targets that behave independently on different pathways, as well as targets that are capable of cross-talking. What’s more, BsAbs are able to target different epitopes on a disease mediator, which can result in enhanced binding and improved neutralization.
With our well-established DT-IgG generation services platform, the experienced scientists here at Creative Biolabs are dedicated to help you develop therapeutic BsAbs. We also provide other various services regarding BsAbs development. Please feel free to contact us for more information and a detailed quote.
1. Kontermann, R.E. Dual targeting strategies with bispecific antibodies. MAbs. 2012, 4(2): 182-197.
2. Zhang, H.; et al. A dual‐targeting antibody against EGFR‐VEGF for lung and head and neck cancer treatment. International journal of cancer. 2012, 131(4): 956-969.
3. Schubert, I.; et al. Dual-targeting for the elimination of cancer cells with increased selectivity. Antibodies. 2012, 1(1): 2-18.